UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes

Diabetes technology & therapeutics, 2019-03, Vol.21 (3), p.110-118

2019

Volltextzugriff (PDF)

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France

PloS one, 2020-01, Vol.15 (1), p.e0226196

2020

Volltextzugriff (PDF)

Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe

BMC cancer, 2013-01, Vol.13 (1), p.10-10, Article 10

2013

Volltextzugriff (PDF)

An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings

Nephrology, dialysis, transplantation, 2003-10, Vol.18 (10), p.2059-2066

2003

Volltextzugriff (PDF)

Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France

Diabetes technology & therapeutics, 2016-02, Vol.18 (2), p.75-84

2016

Volltextzugriff (PDF)

Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes

The New England journal of medicine, 2022-01, Vol.386 (3), p.209-219

2022

Volltextzugriff (PDF)

Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey

Diabetes technology & therapeutics, 2019-12, Vol.21 (12), p.727-735

2019

Volltextzugriff (PDF)

Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective

Journal of medical economics, 2016-03, Vol.19 (3), p.236-242

2016

Volltextzugriff (PDF)

Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands

Journal of medical economics, 2018-09, Vol.21 (9), p.869-877

2018

Volltextzugriff (PDF)

Cost-Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand

Value in health, 2008-03, Vol.11 (s1), p.S43-S51

2008

Volltextzugriff (PDF)

Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain

Endocrinologia, diabetes y nutricion, 2018-08, Vol.65 (7), p.380-386

2018

Volltextzugriff (PDF)

Cost-Effectiveness of Diabetes Case Management for Low-Income Populations

Health services research, 2007-10, Vol.42 (5), p.1943-1959

2007

Volltextzugriff (PDF)

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

Current medical research and opinion, 2007-03, Vol.23 (3), p.609-622

2007

Volltextzugriff (PDF)

An economic assessment of analogue basal–bolus insulin versus human basal–bolus insulin in subjects with type 1 diabetes in the UK

Current medical research and opinion, 2007-04, Vol.23 (4), p.895-901

2007

Volltextzugriff (PDF)

Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study

Current medical research and opinion, 2008-05, Vol.24 (5), p.1417-1428

2008

Volltextzugriff (PDF)

Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH

Advances in therapy, 2006-03, Vol.23 (2), p.191-207

2006

Volltextzugriff (PDF)

Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth With Type 1 Diabetes: A Randomized Trial

Diabetes care, 2024-08, Vol.47 (8), p.1441-1448

2024

Volltextzugriff (PDF)

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making

Current medical research and opinion, 2004-08, Vol.20 Suppl 1, p.S5-26

2004

Volltextzugriff (PDF)

A multivariate logistic regression equation to screen for diabetes: response to Tabaei and Herman

Diabetes care, 2003-05, Vol.26 (5), p.1658-9; author reply 1659

2003

Volltextzugriff (PDF)

Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK

Diabetic medicine, 2005-09, Vol.22 (9), p.1239-1245

2005

Volltextzugriff (PDF)

Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia

Endocrinologia y nutricion, 2016-11, Vol.63 (9), p.466-474

2016

Volltextzugriff (PDF)

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Current medical research and opinion, 2005-12, Vol.21 (12), p.2063-2071

2005

Volltextzugriff (PDF)

Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials

Current medical research and opinion, 2004-11, Vol.20 (11), p.1729-1746

2004

Volltextzugriff (PDF)

Counting the costs of overweight and obesity: modeling clinical and cost outcomes

Current medical research and opinion, 2006-03, Vol.22 (3), p.575-586

2006

Volltextzugriff (PDF)

The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy

Clinical therapeutics, 2003-07, Vol.25 (7), p.2102-2119

2003

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(85)

Sprache

Englisch
(85)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France

Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe

An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings

Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France

Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes

Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey

Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective

Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands

Cost-Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand

Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain

Cost-Effectiveness of Diabetes Case Management for Low-Income Populations

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

An economic assessment of analogue basal–bolus insulin versus human basal–bolus insulin in subjects with type 1 diabetes in the UK

Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study

Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH

Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth With Type 1 Diabetes: A Randomized Trial

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making

A multivariate logistic regression equation to screen for diabetes: response to Tabaei and Herman

Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK

Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials

Counting the costs of overweight and obesity: modeling clinical and cost outcomes

The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy

Aktive Filter

Suchergebnisse filtern